PRN: New Review Explores the Relationship Between Vitamin D and Interferon β-1b in the Treatment of Multiple Sclerosis

19/gen/2016 14.10.19 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

New Review Explores the Relationship Between Vitamin D and Interferon β-1b in the Treatment of Multiple Sclerosis

 
[19-January-2016]
 

LONDON, January 19, 2016 /PRNewswire/ --

- European Neurological Review, the peer-reviewed journal, has published a review discussing the relationship between Vitamin D and Interferon β-1b

There are many reports suggesting an association between vitamin D status and both the development of multiple sclerosis (MS) and its course. This relationship and the effects of vitamin D and interferon β-1b (IFNβ-1b) in the treatment of patients are reviewed in the BEtaferon/ Betaseron in Newly Emerging multiple sclerosis For Initial Treatment (BENEFIT) and the Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in multiple sclerosis (BEYOND) studies. In the BENEFIT study the average serum 25-hydroxyvitamin D (25[OH]D) levels strongly predicted MS disease activity and progression. The probability of clinically definite MS (CDMS) and magnetic resonance imaging (MRI) activity was lower in these clinically isolated syndrome (CIS) patients with 25(OH)D levels ≥50 nmol/L and in those starting with IFNβ -1b. Furthermore, there was a beneficial effect on relapse rate, occurrence of new active MRI lesions and disease progression for a 50 nmol/L increas! e in 25(OH)D levels. Similarly, in relapsing-remitting (RR) MS patients from the BEYOND study serum 25(OH)D levels were inversely associated with MRI markers of MS activity. Genetic analysis of patients from these studies indicated that there may be a benefit in monitoring and managing vitamin D levels in early MS patients treated with IFNβ-1b and a cumulative number of risk alleles predict lower 25(OH)D levels in CIS and RRMS patients. Further studies have suggested that some of the IFNβ-1b therapeutic effects on relapse could be mediated through modulation of vitamin D metabolism. Thus, there seems to be a benefit on clinical and MRI measures if patients are treated with both vitamin D and IFNβ-1b. There is a need to further evaluate this effect in clinical trials. The relationship between vitamin D and MS disease activity along with the effects of vitamin D and IFNβ-1b in the treatment of MS patients is reviewed.

     (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO )

The full peer-reviewed, open-access article is available here:

http://www.touchneurology.com/articles/treatment-multiple-sclerosis-relationship-between-vitamin-d-and-interferon-1b

Note to the Editor

touchNEUROLOGY (a division of Touch Medical Media) publishesEuropean Neurological Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of neurology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day-to-day clinical setting. Practice guidelines, symposium reports, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.

http://www.touchNEUROLOGY.com

Providing practical opinion to support best practice for busy healthcare professionals.

For inquires please contact:

Carla Denaro - Managing Editor
managingeditor@touchmedicalmedia.com
+44-(0)207-193-6093

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl